The outcome of the clinical trials and research efforts of the BPCA program is changing medication labels to improve the knowledge and safe use of those drugs in the pediatric population.
In addition to several label changes, the BPCA program has enabled the development of many resources for researchers, healthcare providers, and the public. These include study summaries, publications, training opportunities, lectures, collaborations, working group recommendations, as well as the BPCA Framework to Enable Pediatric Drug Development, a collection of references specifically identified to assist those involved with pediatric drug development research.
BACK TO TOP